Capricor Therapeutics Faces Class Action Lawsuit Over Securities Violations

Capricor Therapeutics Faces Class Action Suit

In a significant move for shareholders, Capricor Therapeutics, Inc. is facing a class action lawsuit filed by the DJS Law Group. This legal action centers around the company's alleged violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5, as established by the U.S. Securities and Exchange Commission (SEC). Investors who purchased shares in Capricor during the period from December 17, 2025, to July 26, 2026, are encouraged to reach out to the law firm regarding potential lead plaintiff roles.

The lawsuit outlines that Capricor made misleading statements that potentially deceived investors. Specifically, the issue arises from the modifications to the statistical analysis plan pertaining to clinical data for the drug Deramiocel. It has been alleged that the company did not secure prior agreement from the FDA before submitting a Biologics License Application for the drug, resulting in public statements that are now considered false and materially misleading.

As per the complaint, shareholders who faced losses due to these circumstances should consider participating in the lawsuit. The deadline for filing claims is September 28, 2026, emphasizing the urgency for affected investors to act swiftly. DJS Law Group has emphasized their commitment to advocating for investors and aims to assist those impacted by the alleged misstatements by Capricor.

Their legal representation focuses on providing superior advocacy and ensuring that investor rights are upheld. David Schwartz, a founding partner of the firm, specializes in securities issues and has a strong background in corporate governance litigation and overseeing national and international M&A transactions. This expertise positions the firm to not just represent clients but also to strive for optimal restitution for their financial losses.

Moreover, shareholders looking to recover their losses can join the case even without having to take on the role of lead plaintiff. This suggests a collaborative approach where the firm aims to gather a broad representation of affected shareholders to bolster their legal stance against Capricor.

The implications of this legal battle could have far-reaching effects not only for Capricor but also for the broader biopharmaceutical industry, where regulatory compliance and transparent communication are critical for maintaining investor trust. As the case unfolds, it will be essential for stakeholders to closely monitor developments, especially regarding how Capricor responds to these allegations and what actions the SEC might pursue in light of the accusations.

Investors are encouraged to stay informed about the case's progress and consider their options, especially if they hold shares within the specified class period. Taking proactive steps in consultation with legal professionals could help safeguard their financial interests.

With the deadline approaching and potential ramifications for the company's future, while ensuring that governance within the biopharma sector remains a priority, this case is certainly one to watch carefully in the months to come.